Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Gazzard

Showing results (91-100 of 206) with videos related to

Pageof 21
Sort By:
AIDS (London, England)|September 10, 2003
Natural killer cells are not infected by Kaposi's sarcoma-associated herpesvirus in vivo, and natural killer cell counts do not correlate with the risk of developing Kaposi's sarcomaJustin Stebbing, Brian Gazzard, Ornella Flore, et al.
AIDS (London, England)|December 4, 2004
Simplified one-step antibody-HLA directed expansion of HIV-specific cytotoxic T lymphocytes: a system suited for use in vivoJustin Stebbing, Brian Gazzard, Steve Patterson, et al.
The Journal of Antimicrobial Chemotherapy|May 29, 2009
A multicentre cohort experience with double-boosted protease inhibitorsJustin Stebbing, Andrew Scourfield, Gavin Koh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2008
Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infectionThomas Powles, David Robinson, Justin Stebbing, et al.
AIDS (London, England)|February 28, 2008
A long-term durable remission with high-dose therapy and autologous stem cell transplant for stage IVB HIV-associated Hodgkins diseaseIan Gabriel, Jane Apperley, Mark Bower, et al.
Antiviral Therapy|December 3, 2008
Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessationMarta Boffito, Laura Else, David Back, et al.
Antimicrobial Agents and Chemotherapy|June 29, 2011
Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessationMarta Boffito, Akil Jackson, Alieu Amara, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 26, 2011
Combination antiretroviral therapy toxicities: a comparison between patients and health care professionalsMark Nelson, Stuart Yau, Laura Baber, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 1, 2013
Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and preventionAkil Jackson, Graeme Moyle, Victoria Watson, et al.
AIDS (London, England)|August 11, 2007
Virological failure and subsequent resistance profiles in individuals exposed to atazanavirJustin Stebbing, Bif Nathan, Rachael Jones, et al.
Pageof 21

Showing results (91-100 of 206) with videos related to

Sort By:
Pageof 21
AIDS (London, England)|September 10, 2003
Natural killer cells are not infected by Kaposi's sarcoma-associated herpesvirus in vivo, and natural killer cell counts do not correlate with the risk of developing Kaposi's sarcomaJustin Stebbing, Brian Gazzard, Ornella Flore, et al.
AIDS (London, England)|December 4, 2004
Simplified one-step antibody-HLA directed expansion of HIV-specific cytotoxic T lymphocytes: a system suited for use in vivoJustin Stebbing, Brian Gazzard, Steve Patterson, et al.
The Journal of Antimicrobial Chemotherapy|May 29, 2009
A multicentre cohort experience with double-boosted protease inhibitorsJustin Stebbing, Andrew Scourfield, Gavin Koh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2008
Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infectionThomas Powles, David Robinson, Justin Stebbing, et al.
AIDS (London, England)|February 28, 2008
A long-term durable remission with high-dose therapy and autologous stem cell transplant for stage IVB HIV-associated Hodgkins diseaseIan Gabriel, Jane Apperley, Mark Bower, et al.
Antiviral Therapy|December 3, 2008
Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessationMarta Boffito, Laura Else, David Back, et al.
Antimicrobial Agents and Chemotherapy|June 29, 2011
Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessationMarta Boffito, Akil Jackson, Alieu Amara, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 26, 2011
Combination antiretroviral therapy toxicities: a comparison between patients and health care professionalsMark Nelson, Stuart Yau, Laura Baber, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 1, 2013
Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and preventionAkil Jackson, Graeme Moyle, Victoria Watson, et al.
AIDS (London, England)|August 11, 2007
Virological failure and subsequent resistance profiles in individuals exposed to atazanavirJustin Stebbing, Bif Nathan, Rachael Jones, et al.
Pageof 21